Piper Sandler initiated coverage on Merus N.V. (NASDAQ:MRUS), a $2.8 billion market cap biotech company, with an Overweight rating and a price target of $84.00. According to InvestingPro data, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback